Premium
The induction of skin graft tolerance in major histocompatibility complex‐mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti‐CD4 and anti‐CD8 antibodies
Author(s) -
Cobbold Stephen P.,
Martin Gilly,
Waldmann Herman
Publication year - 1990
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830201232
Subject(s) - immunology , biology , cd8 , immune tolerance , immunosuppression , major histocompatibility complex , monoclonal antibody , peripheral tolerance , antibody , antigen , transplantation , cytotoxic t cell , minor histocompatibility antigen , clonal deletion , histocompatibility , clonal anergy , immune system , in vitro , t cell , medicine , t cell receptor , human leukocyte antigen , genetics , surgery
Abstract Mice given short courses of anti‐CD4 and anti‐CD8 monoclonal antibodies became tolerant of allogeneic skin grafted at the same time. Tolerance could be obtained without Tcell depletion across multiple minor antigen mismatches, both in naive and primed animals, demonstrating that peripheral T cells could be tolerized, even if they had been previously activated. Where donor and recipient were incompatible across the whole major histocompatibility complex, specific tolerance could be achieved by using a combination of depleting followed by non‐depleting antibodies, where each alone was unsuccessful. Although mice clearly tolerated their original skin grafts, we observed in some strain combinations that a second fresh, but genotypically identical graft, was slowly rejected. Such mice also possessed Tcells which could proliferate to donor‐type stimulator cells in vitro . Whatever the mechanisms, we have demonstrated that operational transplantation tolerance can be achieved with simple, non‐toxic antibody therapy. The introduction of comparable tolerance‐inducing regimens in clinical organ transplantation could obviate the need for long‐term immunosuppression and its unfortunate side effects.